Peptidyl-prolyl cis-trans isomerase FKBP1A-tacrolimus-calcineurin complex (FKBP12-FK506-CaN complex)

The FKBP1A-tacrolimus-calcineurin complex is a ternary molecular assembly that mediates the potent immunosuppressive effects of the drug tacrolimus, also known as FK506 [StatPearls: NBK544318]. Tacrolimus first binds with high affinity to the intracellular immunophilin FKBP1A (FKBP12), a protein involved in protein folding and calcium channel regulation [UniProt: P62942]. This binary drug-protein complex then acquires the ability to bind and inhibit calcineurin, a calcium-calmodulin-dependent serine/threonine phosphatase [PubMed: 7529402]. By inhibiting calcineurin, the complex prevents the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT), thereby blocking its translocation into the nucleus [PubChem: CID 445643]. This interruption of the signaling pathway prevents the transcription of essential T-cell activation genes, most notably interleukin-2 (IL-2), which is critical for the adaptive immune response [PubMed: 17034344]. Clinically, this target is fundamental for preventing allograft rejection in solid organ transplantation and for treating various inflammatory skin conditions [StatPearls: NBK544318]. However, the ubiquitous expression of calcineurin leads to significant off-target toxicities, such as nephrotoxicity and neurotoxicity, which require careful monitoring of drug concentrations [PubMed: 25831966].

Other names

FKBP12-calcineurin complexTacrolimus-FKBP12-calcineurin complexFK506-FKBP12-calcineurin complexFKBP1A-calcineurin complex

Tacrolimus binds to FKBP1A to form a gain-of-function complex that physically blocks the active site of calcineurin, inhibiting its phosphatase activity and preventing the nuclear translocation of NFAT, which suppresses cytokine transcription.